NCT02869217View on ClinicalTrials.gov

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive PatientsSynovial SarcomaMelanomaEsophageal CancerOvarian CancerLung CancerBladder CancerLiver Cancer
Interventions
DRUG

Cyclophosphamide

BIOLOGICAL

TBI-1301

DRUG

Fludarabine

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
collaborator

Takara Bio Inc.

INDUSTRY

lead

University Health Network, Toronto

OTHER